4/22
08:09 am
RARE
Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) is now covered by analysts at Royal Bank of Canada. They set an "outperform" rating and a $77.00 price target on the stock.
Low
Report
Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) is now covered by analysts at Royal Bank of Canada. They set an "outperform" rating and a $77.00 price target on the stock.
4/22
08:09 am
RARE
Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) is now covered by analysts at Royal Bank of Canada. They set an "outperform" rating and a $77.00 price target on the stock.
Low
Report
Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) is now covered by analysts at Royal Bank of Canada. They set an "outperform" rating and a $77.00 price target on the stock.
4/22
05:40 am
RARE
Rating for RARE
Low
Report
Rating for RARE
4/22
05:40 am
RARE
Rating for RARE
Low
Report
Rating for RARE
4/17
01:19 pm
RARE
Rating for RARE
Low
Report
Rating for RARE
4/17
01:19 pm
RARE
Rating for RARE
Low
Report
Rating for RARE
4/16
10:55 am
RARE
Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) had its "neutral" rating re-affirmed by analysts at Wedbush. They now have a $48.00 price target on the stock.
Low
Report
Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) had its "neutral" rating re-affirmed by analysts at Wedbush. They now have a $48.00 price target on the stock.
4/16
10:55 am
RARE
Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) had its "neutral" rating re-affirmed by analysts at Wedbush. They now have a $48.00 price target on the stock.
Low
Report
Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) had its "neutral" rating re-affirmed by analysts at Wedbush. They now have a $48.00 price target on the stock.
4/16
10:19 am
RARE
Rating for RARE
Low
Report
Rating for RARE
4/16
10:19 am
RARE
Rating for RARE
Low
Report
Rating for RARE
4/5
10:26 am
RARE
Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald. They now have a $107.00 price target on the stock.
Medium
Report
Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald. They now have a $107.00 price target on the stock.
4/5
09:19 am
RARE
Rating for RARE
Medium
Report
Rating for RARE
3/18
07:54 am
RARE
Rating for RARE
Low
Report
Rating for RARE
2/27
01:13 pm
RARE
Rating for RARE
Low
Report
Rating for RARE
2/27
10:17 am
RARE
Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald. They now have a $107.00 price target on the stock.
Medium
Report
Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald. They now have a $107.00 price target on the stock.
2/27
09:22 am
RARE
Rating for RARE
Medium
Report
Rating for RARE
2/21
09:12 am
RARE
Rating for RARE
Low
Report
Rating for RARE
2/16
08:53 am
RARE
Rating for RARE
Low
Report
Rating for RARE
2/16
08:53 am
RARE
Rating for RARE
Low
Report
Rating for RARE
2/15
09:18 am
RARE
Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald. They now have a $114.00 price target on the stock.
Low
Report
Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald. They now have a $114.00 price target on the stock.
2/15
09:12 am
RARE
Rating for RARE
Low
Report
Rating for RARE
1/30
01:39 pm
RARE
Rating for RARE
Low
Report
Rating for RARE
1/30
01:39 pm
RARE
Rating for RARE
Low
Report
Rating for RARE